An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2019
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms ECZTEND
- Sponsors LEO Pharma
- 23 Oct 2018 Planned End Date changed from 7 Jun 2021 to 13 Sep 2021.
- 23 Oct 2018 Planned primary completion date changed from 31 May 2021 to 7 Jun 2021.
- 10 Sep 2018 Planned initiation date changed from 20 Aug 2018 to 20 Sep 2018.